Neonatal Hearing Screening in Assiut Hospital

NCT ID: NCT03251638

Last Updated: 2017-08-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-03-31

Study Completion Date

2018-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hearing loss is one of the most common congenital anomalies. Early Intervention at or before 6 months of age allows a child with impaired hearing to develop normal speech and language.Auditory brainstem response , otoacoustic emissions testing have all been used in newborn hearing-screening programs

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hearing loss is one of the most common congenital anomalies . It has been shown to be greater than that of most other diseases and syndromes (eg, phenylketonuria, sickle cell disease) screened at birth . Data from the newborn hearing-screening programs in Rhode Island, Colorado, and Texas showed that 2-4 of every 1000 neonates have hearing loss.

Early Intervention at or before 6 months of age allows a child with impaired hearing to develop normal speech and language, alongside his or her hearing peers and can prevent severe psychosocial, educational, and language impairment.( One of the most high risk population are neonates who spend time in the newborn intensive care unit, exposed to high frequency ventilation, hyperbilirubinemia, low birth-weight, and exposed to ototoxic medications.

Auditory brainstem response, otoacoustic emissions , and automated Auditory brainstem response testing have all been used in newborn hearing-screening programs. otoacoustic emissions are fast objective, efficient, and frequency-specific measurements of peripheral auditory sensitivity are used to assess response of the outer hair cells to acoustic stimuli. To measure otoacoustic emissions, a probe assembly is placed in the ear canal, tonal or click stimuli are delivered, and the otoacoustic emissions generated by the cochlea is measured with a microphone .

Currently, 2 types of evoked otoacoustic emissions measurements are used for newborn hearing screening: transient evoked otoacoustic emissions and distortion product otoacoustic emissions . Provided that the patient's middle ear function is normal, these measurements can be used to assess cochlear function for the 500-6000 Hz frequency range. The presence of evoked otoacoustic emissions responses indicates hearing sensitivity in the normal to near-normal range .

The Auditory brainstem response test records brainstem electrical activity in response to sounds presented to the infant via earphones. In contrast to the otoacoustic emissions test, the The Auditory brainstem response evaluates the auditory pathway from the external ear to the level of the brainstem, enabling diagnosis of auditory neuropathy, which is a less common cause of hearing impairment .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neonatal Hearing Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A) Neonates of both sexes. (B) Neonates with the following risk factors according to the Joint Committee on Infant Hearing 2000 Position Statement:

* In utero infection such as cytomegalovirus, rubella, toxoplasmosis, or herpes.
* Neonatal indicators, specifically hyperbilirubinemia at a serum level requiring exchange transfusion, persistent pulmonary hypertension of the newborn associated with mechanical ventilation, and conditions requiring the use of extracorporeal membrane oxygenation
* Low birth weight (1500-1800)grams

Exclusion Criteria

* • Absence of high risk factors in the neonates.
Minimum Eligible Age

1 Day

Maximum Eligible Age

1 Month

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nesma Gamal

Neonatal Hearing Screeing at Neonatal Intensive Care Unit of Assiut University Hospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nafesa Hs Rafat, Prof

Role: STUDY_DIRECTOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Eman AF Sayed, As.Prof

Role: CONTACT

0201156383841

Samah M Ahmed, lecturer

Role: CONTACT

0201003272437

References

Explore related publications, articles, or registry entries linked to this study.

Connolly JL, Carron JD, Roark SD. Universal newborn hearing screening: are we achieving the Joint Committee on Infant Hearing (JCIH) objectives? Laryngoscope. 2005 Feb;115(2):232-6. doi: 10.1097/01.mlg.0000154724.00787.49.

Reference Type RESULT
PMID: 15689741 (View on PubMed)

Downs MP. Universal newborn hearing screening--the Colorado story. Int J Pediatr Otorhinolaryngol. 1995 Jul;32(3):257-9. doi: 10.1016/0165-5876(95)01183-c.

Reference Type RESULT
PMID: 7665273 (View on PubMed)

Erenberg A, Lemons J, Sia C, Trunkel D, Ziring P. Newborn and infant hearing loss: detection and intervention.American Academy of Pediatrics. Task Force on Newborn and Infant Hearing, 1998- 1999. Pediatrics. 1999 Feb;103(2):527-30. doi: 10.1542/peds.103.2.527.

Reference Type RESULT
PMID: 9925859 (View on PubMed)

Finitzo T, Albright K, O'Neal J. The newborn with hearing loss: detection in the nursery. Pediatrics. 1998 Dec;102(6):1452-60. doi: 10.1542/peds.102.6.1452.

Reference Type RESULT
PMID: 9832584 (View on PubMed)

Williams TR, Alam S, Gaffney M; Centers for Disease Control and Prevention (CDC). Progress in identifying infants with hearing loss-United States, 2006-2012. MMWR Morb Mortal Wkly Rep. 2015 Apr 10;64(13):351-6.

Reference Type RESULT
PMID: 25856256 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Assuit

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cohort Of DEafness-gene Screening
NCT06133946 ACTIVE_NOT_RECRUITING